187420.Kq
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, production, and sale of pharmaceutical products.
The company maintains a capital structure with a debt-to-equity ratio of 1.06, indicating a moderate reliance on debt financing. Its liquidity position is characterized by a current ratio of 0.79, suggesting potential short-term liquidity constraints. The company holds cash and equivalents of 33,481,640,000 KRW, but this is offset by long-term debt of 43,524,347,310 KRW, resulting in a net cash position that is negative.
Profitability metrics show a return on equity of 55.21% and a return on assets of 16.63%, both of which are strong indicators of efficient capital use and asset management. These figures suggest the company is outperforming typical industry benchmarks for profitability, although specific industry medians are not provided in the available data.
The company's revenue is not segmented by geographic region or product line in the available data, so it is not possible to assess geographic or segment concentration. However, the lack of segmentation detail implies that the company may have a concentrated revenue base, which could pose a risk if a key market or product line underperforms.
The company's growth trajectory is not explicitly outlined in the available data, and no numeric deltas for the current or next fiscal year are provided. The absence of forward-looking guidance makes it difficult to assess the company's expected growth rate or strategic direction.
The risk assessment indicates a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could impact its ability to meet short-term obligations without additional financing. No specific dilution sources are identified in the available data, and the dilution risk is assessed as low, suggesting that the company is not expected to issue additional shares in the near term.
Recent events, such as filings or transcripts, are not detailed in the available data, so it is not possible to assess the company's recent performance or strategic developments. The absence of recent events data limits the ability to evaluate the company's current market position or operational changes.
- The company has a strong return on equity of 55.21%, indicating efficient use of shareholder capital.
- The company's liquidity position is constrained, with a current ratio of 0.79.
- The company's net cash position is negative after accounting for long-term debt, which could affect its short-term financial flexibility.
- The company's growth trajectory and strategic direction are not clearly defined in the available data.
- The company is assessed to have a low dilution risk, suggesting no immediate pressure to issue additional shares.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 187420.KQ Market data — financials · 2026-05-26
- HLB Genex Inc Market data — analyst estimates · 2026-05-26